Bosun Asset Management LLC Lowers Stock Position in Twist Bioscience Co. (NASDAQ:TWST)

Bosun Asset Management LLC lessened its position in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 49.3% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 8,091 shares of the company's stock after selling 7,876 shares during the quarter. Bosun Asset Management LLC's holdings in Twist Bioscience were worth $376,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Arizona State Retirement System boosted its position in Twist Bioscience by 1.3% during the fourth quarter. Arizona State Retirement System now owns 16,985 shares of the company's stock worth $789,000 after purchasing an additional 219 shares in the last quarter. Van ECK Associates Corp raised its stake in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company's stock worth $34,000 after buying an additional 267 shares during the period. Hillsdale Investment Management Inc. lifted its position in shares of Twist Bioscience by 0.4% during the 4th quarter. Hillsdale Investment Management Inc. now owns 78,000 shares of the company's stock valued at $3,625,000 after buying an additional 300 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in Twist Bioscience by 7.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,098 shares of the company's stock worth $283,000 after acquiring an additional 443 shares in the last quarter. Finally, US Bancorp DE raised its position in Twist Bioscience by 72.0% during the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock worth $67,000 after acquiring an additional 601 shares during the period.

Insider Activity

In other Twist Bioscience news, Director Robert Chess sold 2,940 shares of the company's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $53.13, for a total value of $156,202.20. Following the transaction, the director now owns 18,173 shares of the company's stock, valued at $965,531.49. This represents a 13.93 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Paula Green sold 918 shares of Twist Bioscience stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the sale, the senior vice president now owns 130,912 shares of the company's stock, valued at approximately $5,355,609.92. This represents a 0.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 12,137 shares of company stock valued at $530,112 in the last quarter. Insiders own 3.01% of the company's stock.

Twist Bioscience Trading Down 8.9 %

Shares of TWST stock opened at $32.75 on Wednesday. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a twelve month low of $32.63 and a twelve month high of $60.90. The company's 50-day moving average price is $39.02 and its 200-day moving average price is $43.90. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -9.69 and a beta of 2.54.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.10). The firm had revenue of $92.79 million during the quarter, compared to analysts' expectations of $92.00 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. As a group, equities analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently weighed in on TWST. The Goldman Sachs Group reduced their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating for the company in a research report on Tuesday. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Guggenheim reaffirmed a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday. Robert W. Baird reduced their price objective on Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research note on Tuesday. Finally, Barclays dropped their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, April 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, Twist Bioscience presently has an average rating of "Moderate Buy" and an average target price of $50.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Co. (NASDAQ:TWST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.